Welcome!
Seelos Therapeutics
Corporate moves
iX Biopharma aims for stronger growth momentum with Seelos licensing deal
iX Biopharma announces an outlicensing agreement worth more than $300 million (excluding royalties) with Seelos Therapeutics
January 13, 2022
Healthcare
iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil
iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
November 24, 2021